Evidence map›Paper›PMID 42497015›Full record

ArticleCritical care explorations2026

Clinical and Culture-Based Predictors of Gut Microbiome Alpha Diversity at the Time of ICU Admission.

Dakota Ma, Anne-Catrin Uhlemann, Julian A Abrams, Daniel E Freedberg

Registry-linked trialAbstract read
In one paragraph

Article in Critical care explorations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03865706 (Prebiotic Inulin to Limit Antimicrobial-Resistant Infections During Critical Illness), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03865706 phase2completednot on this map

Prebiotic Inulin to Limit Antimicrobial-Resistant Infections During Critical Illness: A Phase II Clinical Trial

TypeinterventionalSponsorColumbia UniversityRan2019 to 2024Enrolled94ConditionsAntibiotic Resistant Infection, Nosocomial Infection, Pathogen Transmission, Nutrition DisordersArmsInulin Oral Suspension, Placebo Oral Suspension, Broad-spectrum antibiotics
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Can We Identify Severe Dysbiosis at the Bedside?Critical care explorations · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dakota MaColumbia University Vagelos College of Physicians and Surgeons, New York, NY.ORCID 0000-0003-3223-3717
Anne-Catrin UhlemannDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY.
Julian A AbramsDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY.
Daniel E FreedbergDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY.

Funding

The Organoid and Cell Culture CoreP30DK132710 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Jianwen Que · 2022 to 2026
$7.2M
Training Medical Students in NIDDK ResearchT35DK093430 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI QAIS AL-AWQATI, Utpal Pajvani · 2012 to 2026
$1.3M
NIDDK NIH HHS P30 DK132710NIDDK NIH HHS T35 DK093430
6 · The paper itself

Abstract

objectivesMicrobiome-based therapies to improve gut colonization resistance are being developed for the ICU, but their efficacy may depend on the baseline gut microbiome at ICU admission. We sought to identify clinical predictors of alpha diversity at ICU admission.

designRetrospective reanalysis of a randomized clinical trial (NCT03865706).

settingSingle-center ICU. PATIENTS: ICU patients with sepsis as the primary diagnosis who were receiving broad-spectrum antibiotics and could be enrolled within 24 hours of ICU admission.

interventionsNone. MEASUREMENTS AND MAIN

resultsDemographic and clinical characteristics for medical ICU patients with sepsis were recorded during a previously published randomized clinical trial. Deep rectal swabs were collected within 24 hours of ICU admission and sequenced to describe alpha diversity (Shannon index) and cultured for vancomycin-resistant Enterococcus (VRE). Patients were organized into tertiles of Shannon diversity (low, middle, high) with a primary outcome of a lower Shannon tertile at ICU admission. Overall, 90 patients were enrolled. The three variables of location before ICU admission (adjusted odds ratio [aOR], 3.54; 95% CI, 1.21-10.3 for ICU transfer vs. emergency department [ED]; aOR, 6.09; 95% CI, 1.89-19.6 for hospital ward vs. ED), prior culture-proven infection within 1 year (aOR, 2.46; 95% CI, 1.02-5.96), and VRE status on ICU admission (aOR, 4.18; 95% CI, 1.44-12.1 for positive vs. negative swab) were sufficient to describe a quasi-linear trend in alpha diversity at ICU admission.

conclusionsBaseline gut microbiome Shannon alpha diversity at ICU admission could be described with three readily ascertained clinical variables. Our model shows promise as a preliminary framework of factors that collectively best predict baseline alpha diversity at ICU admission and warrants validation in larger independent cohorts.

Indexed as

Gastrointestinal MicrobiomeIntensive Care UnitsSepsisAgedAnti-Bacterial AgentsFemaleHumansMaleMiddle AgedRandomized Controlled Trials as TopicRetrospective StudiesVancomycin-Resistant EnterococciAnti-Bacterial Agentsclinical predictorsgut microbiomeintensive care unitShannon alpha diversitystool culture

Identifiers

PMID42497015
PMCPMC13406136

What Socratic holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.